NCT04765098View on ClinicalTrials.gov

Tamoxifen Versus Etoposide After First Recurrence in GBM Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 28, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

July 31, 2027

Conditions
Glioblastoma Multiforme
Interventions
DRUG

Tamoxifen

Tamoxifen 20 mg daily for 3 days then 20 mg BID for 3 days then increase by 20 mg daily every 3 days until 100 mg BID continuously

DRUG

Etoposide

etoposide 50mg/m2 daily

Trial Locations (1)

Unknown

RECRUITING

Cross Cancer Institute, Edmonton

All Listed Sponsors
lead

AHS Cancer Control Alberta

OTHER